CLINICAL_TRIALS ClinicalTrials.gov record update

Repurposing Mefloquine for Pancreatic Cancer Treatment

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07875907
Title field or adapter rule: {'original_value': 'Repurposing Mefloquine for Pancreatic Cancer Treatment', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:23.401877+00:00
Published At: 2026-10-15T00:00:00+00:00
Record Updated At: 2026-10-15
Source Retrieved At: 2026-10-31T22:17:52.415050+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Pancreatic Ductal Adenocarcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-15", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT07875907"
protocolSection.identificationModule.officialTitle: "Repurposing Mefloquine for Pancreatic Cancer Treatment"
protocolSection.statusModule.overallStatus: "NOT_YET_RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['Mefloquine + gemcitabine and nab-paclitaxel', 'Mefloquine + modified FOLFIRINOX', 'Mefloquine monotherapy'], 'description': 'Subjects will take a loading dose of 250 mg orally of mefloquine once daily on days -7, -6 and -5. Then, beginning on day 1, subjects will take 250 mg of mefloquine orally either once a week or once every 2 weeks.\n\nDose assignment will follow a 3 + 3 design for each arm, with once a week dosing as the starting dose. Three subjects will enroll in weekly dosing; if none or only one experiences a dose-limiting toxicity DLT, the recommended Phase 2 dose for that arm will be 250 mg weekly after a loading dose. If more than one subject experiences a DLT, the dose will be reduced to once every 2 weeks, and the process will repeat. If 2 or more DLTs occur at the reduced dose level, dosing will cease. Treatment will continue for all subjects until unacceptable toxicity, patient preference or disease progression. For arms that include concurrent chemotherapy (modified FOLFIRINOX or gemcitabine and nab-paclitaxel), concurrent chemotherapy will start on day 1.', 'name': 'Mefloquine', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Mefloquine + modified FOLFIRINOX'], 'description': "Subjects will receive modified FOLFIRINOX beginning on day 1. Dosing of modified FOLFIRINOX will be per standard of care guidelines and the treating physician's discretion.", 'name': 'Modified FOLFIRINOX', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['Mefloquine + gemcitabine and nab-paclitaxel'], 'description': "Subjects will receive gemcitabine and nab paclitaxel beginning on day 1. Dosing of gemcitabine and nab paclitaxel will be per standard of care guidelines and the treating physician's discretion.", 'name': 'gemcitabine and nab paclitaxel', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.